Copyright
©The Author(s) 2024.
World J Clin Cases. Nov 6, 2024; 12(31): 6451-6461
Published online Nov 6, 2024. doi: 10.12998/wjcc.v12.i31.6451
Published online Nov 6, 2024. doi: 10.12998/wjcc.v12.i31.6451
Table 3 Comparison of different immunotherapies for allergic rhinitis
Method | Delivery route | Mechanism | Safety |
SCIT | Subcutaneous (systemic) injection | IgG4 antibody induction[41] | Higher rates of systemic reactions[40] |
SLIT | Sublingual (local) administration | IgA antibody induction[41] | Fewer systemic reactions than SCIT[40] |
OIT | Oral cavity/gastrointestinal tract | Suppression of allergen-specific T-cell proliferation[50] | Oral pruritus[53] |
ILIT | Lymph nodes | IgG4 antibody induction[54] | Safer than SCIT[58] |
GIASIT | Intravenous infusion | Increased plasma gelsolin levels[59] | Mild side effects[59] |
Combination of AIT and monoclonal antibody therapy | Subcutaneous monoclonal antibody and AIT route | Omalizumab (anti-IgE). Dupilumab (anti-IL4Rα). Tezepelumab (anti-TSLP)[62-64] | Mild or moderate application-site reactions[63] |
- Citation: Fu Y, Song YL, Liu ZG. Recent developments in immunotherapy approaches for allergic rhinitis. World J Clin Cases 2024; 12(31): 6451-6461
- URL: https://www.wjgnet.com/2307-8960/full/v12/i31/6451.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i31.6451